The role of epidemiology in the introduction of Vi polysaccharide typhoid fever vaccines in Asia

被引:0
|
作者
Acosta, CJ
Galindo, CM
Ochiai, RL
Carolina, M
Danovaro-Holliday, MC
Page, AL
Thiem, VD
Park, JK
Park, E
Koo, H
Wang, XY
Abu-Elyazeed, R
Ali, M
Albert, MJ
Ivanoff, B
Pang, TK
Xu, ZY
Clemens, JD
机构
[1] Int Vaccine Inst, Seoul 151818, South Korea
[2] Natl Inst Hyg & Epidemiol, Hanoi, Vietnam
[3] US NAMRU 3, Enter Dis Res Program, Epidemiol Unit, Cairo, Egypt
[4] GlaxoSmithKline BIol, Singapore, Singapore
[5] Kuwait Univ, Fac Med, Dept Microbiol, Kuwait, Kuwait
[6] WHO, Vaccines & Other Biol, CH-1211 Geneva, Switzerland
[7] WHO, Res Policy & Cooperat, CH-1211 Geneva, Switzerland
[8] NICHHD, Bethesda, MD 20892 USA
关键词
typhoid fever; vaccine; epidemiology; vaccinology; Salmonella typhi; Asia;
D O I
暂无
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Despite the availability of at least two licensed typhoid fever vaccines-injectable sub-unit Vi polysaccharide vaccine and live, oral Ty21a vaccine-for the last decade, these vaccines have not been widely introduced in public-health programmes in countries endemic for typhoid fever. The goal of the multidisciplinary DOMI (Diseases of the Most Impoverished) typhoid fever programme is to generate policy-relevant data to support public decision-making regarding the introduction of Vi polysaccharide typhoid fever immunization programmes in China, Viet Nam, Pakistan, India, Bangladesh, and Indonesia. Through epidemiological studies, the DOMI Programme is generating these data and is offering a model for the accelerated, rational introduction of new vaccines into health programmes in low-income countries. Practical and specific examples of the role of epidemiology are described in this paper. These examples cover: (a) selection of available typhoid fever vaccines to be introduced in the programme, (b) generation of policy-relevant data, (c) providing the 'backbone' for the implementation of other multidisciplinary projects, and (d) generation of unexpected but useful information relevant for the introduction of vaccines. Epidemiological studies contribute to all stages of development of vaccine evaluation and introduction.
引用
收藏
页码:240 / 245
页数:6
相关论文
共 50 条
  • [21] Vaccines for preventing typhoid fever
    Anwar, Elspeth
    Goldberg, Elad
    Fraser, Abigail
    Acosta, Camilo J.
    Paul, Mical
    Leibovici, Leonard
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (01):
  • [22] Progress in Typhoid Fever Epidemiology
    Crump, John A.
    CLINICAL INFECTIOUS DISEASES, 2019, 68 : S4 - S9
  • [23] PROTECTIVE ACTIVITY OF VI-CAPSULAR POLYSACCHARIDE VACCINE AGAINST TYPHOID-FEVER
    KLUGMAN, KP
    KOORNHOF, HJ
    SCHNEERSON, R
    CADOZ, M
    GILBERTSON, IT
    ROBBINS, JB
    SCHULZ, D
    ARMAND, J
    LANCET, 1987, 2 (8569): : 1165 - 1169
  • [24] Epidemiology of typhoid fever in Mauritius
    Issack, MI
    JOURNAL OF TRAVEL MEDICINE, 2005, 12 (05) : 270 - 274
  • [25] Why are typhoid vaccines not recommended for epidemic typhoid fever?
    Taylor, DN
    Levine, MM
    Kuppens, L
    Ivanoff, B
    JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (06): : 2089 - 2090
  • [26] A Review of the Economic Evidence of Typhoid Fever and Typhoid Vaccines
    Luthra, K.
    Watts, E.
    Debellut, F.
    Pecenka, C.
    Bar-Zeev, N.
    Constenla, D.
    CLINICAL INFECTIOUS DISEASES, 2019, 68 : S83 - S95
  • [27] Vaccines for typhoid fever and other salmonelloses
    Martin, Laura B.
    CURRENT OPINION IN INFECTIOUS DISEASES, 2012, 25 (05) : 489 - 499
  • [28] TYPHOID-FEVER VACCINES - COMMENTARY
    GARDNER, P
    INFECTIOUS DISEASES IN CLINICAL PRACTICE, 1995, 4 (06) : 465 - 465
  • [29] The therapeutic use of vaccines in typhoid fever
    Callison, JG
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1912, 144 : 350 - 360
  • [30] Vaccines for preventing typhoid fever (Review)
    Milligan, Rachael
    Paul, Mical
    Richardson, Marty
    Neuberger, Ami
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (05):